Access
To read this story in full you will need to login or make a payment (see right).
Insight
Nature 441, 457-462 (25 May 2006) | doi:10.1038/nature04874; Published online 24 May 2006
Open Innovation Challenges
- More Challenges
- Powered by:
nature jobs
Sr. Scientific Manager / Chief Scientific Manager- Discovery Metabolism and Pharmacokinetics (MAP)
- Syngene International
- Bangalore, Karnataka 560099 India
Senior Lecturer / Lecturer in Filarial Parasitology
- LSTM
- Liverpool, United Kingdom
Review article Mechanisms of drug inhibition of signalling molecules
Judith S. Sebolt-Leopold1 & Jessie M. English2
Abstract
The emergence of tumour-specific, molecularly targeted agents signifies a paradigm shift in cancer therapy, with less reliance on drugs that non-discriminately kill tumour and host cells. Although the diversity of targets giving rise to this new generation of anticancer drugs has expanded, many challenges persist in the design of effective treatment regimens. The complex interplay of signal-transduction pathways further complicates the customization of cancer treatments to target single mechanisms. However, despite uncertainty over precise or dominant mechanisms of action, especially for compounds targeting multiple gene products, emerging agents are producing significant therapeutic advances against a broad range of human cancers.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Killing two kinase families with one stoneNature Chemical Biology News and Views (01 Nov 2008)
